Location of Repository

Pharmacogenetics of ophthalmic topical β-blockers\ud

By Duska J. Sidjanin, Catherine A. McCarty, Richard Patchett, Edward M. Smith and Russell A. Wilke

Abstract

Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical β-blockers. This review summarizes clinically significant polymorphisms that have been identified in the β-adrenergic receptors (ADRB1, ADRB2 and ADRB3). The implications of polymorphisms in CYP2D6 are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basis of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical β-blockers may advance individualized treatment at a lower cost.\ud \u

Topics: RE
Publisher: Future Medicine Ltd.
Year: 2008
OAI identifier: oai:wrap.warwick.ac.uk:3628

Suggested articles

Preview

Citations

  1. (2005). Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002;295:1077–1079. [PubMed: 11834836] 12. Monemi doi
  2. (2009). Advances in the management of paediatric glaucoma. Eye 2007;21:1319– 1325. [PubMed: 17914435] 17. Enyedi doi
  3. (2009). Anterior chamber Structures involved in aqueous humor production and outflow in the eye Sidjanin et al. Page 13 Per Med. Author manuscript; available in PMC
  4. Combinatorial pharmacogenetics. Nat Rev Drug Discov 2005;4:911– 918. [PubMed: 16264434] 65. Wilke doi
  5. (2009). Global data on visual impairment in the year 2002. Bull World Health Organ 2002;82:844–851. [PubMed: 15640920] Sidjanin et al. Page 7 Per Med. Author manuscript; available in PMC
  6. (2009). Graefes Arch Klin Exp Ophthalmol 1980;213:19–22. [PubMed: 6906142] 33. Fiscella
  7. Identification of a gene that causes primary open angle glaucoma. Science 1997;275:668–670. [PubMed: 9005853] 9. Suzuki
  8. Increased risk of obesity resulting from the interaction between high energy intake and the Trp64Arg polymorphism of the β3-adrenergic receptor gene in healthy Japanese men. J Epidemiol 2005;15:203–210. [PubMed: 16276029] 52. Hao doi
  9. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large, population-based biobank. doi
  10. (1998). New thoughts on normal tension glaucoma. Optometry 2005;76:600–608. [PubMed: 16230276] 5. Alward WL. Medical management of glaucoma.
  11. (1978). Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007;67:237–245. [PubMed: 17366003] 28. Leier CV, doi
  12. (2009). Page 10 Per Med. Author manuscript; available in PMC
  13. Polymorphism of β-adrenergic receptors and susceptibility to open-angle glaucoma. Mol Vis 2006;12:673–680. [PubMed: 16785856] 58. Gungor
  14. (2002). Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. doi
  15. β-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. Kidney Int 1998;53:1455–1460. [PubMed: 9607174] 48. Lanfear doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.